PRIZM PHARMA INC has a total of 22 patent applications. Its first patent ever was published in 1993. It filed its patents most often in WIPO (World Intellectual Property Organization), Australia and Canada. Its main competitors in its focus markets biotechnology, pharmaceuticals and environmental technology are CHO PHARMA USA INC, NKARTA INC and ORIGINCELL THERAPEUTICS CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 7 | |
#2 | Australia | 6 | |
#3 | Canada | 4 | |
#4 | EPO (European Patent Office) | 4 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Environmental technology | |
#4 | Medical technology | |
#5 | Measurement |
# | Name | Total Patents |
---|---|---|
#1 | Sosnowski Barbara A | 17 |
#2 | Baird J Andrew | 12 |
#3 | Nova Michael P | 9 |
#4 | Houston L L | 8 |
#5 | Baird Andrew J | 5 |
#6 | Lappi Douglas A | 4 |
#7 | Chandler Lois A | 3 |
#8 | Pierce Glenn | 3 |
#9 | Chandler Lois Ann | 3 |
#10 | Mcdonald John R | 2 |
Publication | Filing date | Title |
---|---|---|
AU6339198A | Inhibitors of leaderless protein export | |
CA2221269A1 | Compositions containing nucleic acids and ligands for therapeutic treatment | |
AU3724495A | Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents | |
WO9606641A1 | Conjugates of vascular endothelial growth factor with targeted agents | |
WO9524928A2 | Heparin-binding growth factors for gene therapy and anterior eye disorders | |
WO9503831A1 | Monogenous preparations of cytotoxic conjugates |